Abstract: An apparatus for converting a barbecue into a pizza cooking oven includes an open door frame and vertical side panels pivotally attached to the vertical side posts of the open door frame. The side panels can be pivotally adjusted on the open door frame to extend rearward of the open door frame at different pivot positions. When the side panels are extended rearward of the open door frame, the bottom edges of the side panels provide a support base for setting the apparatus onto the top rim of a bottom bowl of a barbecue and the top edges of the side panels support a cover of a barbecue in an elevated position above the bottom bowl of the barbecue. The elevation of the cover creates an expanded cooking chamber above the bottom bowl of the barbecue and the open door frame provides access to the expanded cooking chamber.
Type:
Grant
Filed:
July 22, 2016
Date of Patent:
March 26, 2019
Assignee:
Charcoal Companion Incorporated
Inventors:
Cory Thomas Borovicka, Kwame Phillips-Solomon
Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.
Abstract: The invention relates to methods to identify compounds that can treat autoimmune conditions and treat specified clinical disorders such as multiple sclerosis, ulcerative colitis or arthritis. Compounds include 17?-ethynylandrost-5-ene-3?,11?,7?,17?-tetrol, 4?-acetoxy-17?-ethynylandrost-5-ene-3?,7?,17?-triol, 17?-ethynylandrost-5-ene-3?,4?,7?,17?-tetrol, 17?-ethynylandrost-5-ene-3?,4?,7?,17?-tetrol and 17?-ethynylandrost-5-ene-3?,4?,17?-triol-7-one.
Type:
Application
Filed:
November 17, 2007
Publication date:
June 26, 2008
Inventors:
James M. Frincke, Christopher Reading, Dominick Auci, Clarence N. Ahlem
Abstract: The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or reduce the symptoms of allergic and/or inflammatory conditions in a mammalian patient. The invention also provides methods and compositions, which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects.
Type:
Application
Filed:
May 17, 2005
Publication date:
June 12, 2008
Inventors:
Adrian Ashley, Paul Lamb, Donald MacDonald, John Miller, Martin J. Oliver, Mathew Pollard
Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.
Type:
Grant
Filed:
April 25, 1997
Date of Patent:
April 6, 1999
Assignee:
The Children's Medical Center Corporation
Inventors:
Robert John D'Amato, Moses Judah Folkman
Abstract: The invention is directed to novel steroid intermediate products of general formula I ##STR1## The steroid intermediate products which can be isolated according to the invention are suitable for the synthesis of 13-ethyl-11-methylene-18,19-bisnor-17.alpha.-pregn-4-en-20-in-17-ol (desogestrel).Further, processes for producing the steroid intermediate products of general formula I are described. The olefination of the 11-oxo steroids is carried out under the influence of ultrasound.
Type:
Grant
Filed:
September 9, 1994
Date of Patent:
November 3, 1998
Assignee:
Jenapharm GmbH
Inventors:
Sven Ring, Gerhard Teichmueller, Gisela Weber, Sigfrid Schwarz, Bernd Erhart, Bernd Undeutsch, Harald Raethe, Peter Moellmann, Carmen Pfeiffer, Hans-Joachim Palme
Abstract: The unsaturated 17.alpha.-cyanomethyl-17.beta.-hydroxy steroids of the formula I, ##STR1## in which R.sub.1 =Me, Eth; R.sub.2 =H, Me; R.sub.3 =H, OH, an acetoxy or alkoxy group; R.sub.4 =H, R.sub.5 =OH, an acetoxy, alkoxy group of R.sub.4 and R.sub.5 together represent a keto- or ketal group and double bonds are contained in the basic structure of the steroid, particularly between the 15 and 16 position in the steroid ring, from unsaturated 17-ketosteroids of the general formula II as described herein with the aforementioned meanings of R.sub.1 to R.sub.5 by reacting the unsaturated 17-ketosteroids with LiCH.sub.2 CN and subsequently hydrolyzing.The compounds of formula I are pharmacologically interesting steroid compounds or also intermediate products for the synthesis of highly-effective steroid products which can be used in human and veterinary medicine for the treatment of endocrine disorders and for reproductive control based on their specific hormonal/anti-hormonal actions.
Abstract: The present invention involves improved processes for the dehalogenation of 9.alpha.-halosteroids (I) ##STR1## to produce the corresponding 11.beta.-hydroxy steroids (II) ##STR2## which are known to be useful as pharmaceutical, where the improvements comprise (1) adding the 9.alpha.-halo steroid (I) to the chromium and (2) using catalytic amounts of chromium in the presence of a means of converting chromium (II) to chromium (III).
Abstract: Novel tricyclic steroid analogs are disclosed which are 1H-benz[e]indene dodecahydro compounds that are useful for enhancing GABA-induced chloride currents at the GABA receptor/chloride ionophore complex and can be represented by the following structural formulas: ##STR1## wherein R.sub.1 =H or C.sub.1 -C.sub.4 alkyl or fluoroalkyl;R.sub.2 =H or C.sub.1 -C.sub.4 alkyl or fluoroalkyl, in which R.sub.1 and R.sub.2 can be the same or different;R.sub.3 =H or CH.sub.3 ;R.sub.4 =H or CH.sub.3, in which R.sub.3 and R.sub.4 can be the same or different;R.sub.5 =H;R.sub.6 =H;R.sub.5,R.sub.6 =.dbd.O(carbonyl);R.sub.7 =H;R.sub.8 =a hydrogen bond accepting group.R.sub.7,R.sub.8 =.dbd.O(carbonyl); andR'=an ester group.
Type:
Grant
Filed:
January 14, 1993
Date of Patent:
March 8, 1994
Assignee:
Washington University
Inventors:
Douglas F. Covey, Yuefei Hu, Charles F. Zorumski